国际妇产科学杂志

国际妇产科学杂志 ›› 2016, Vol. 43 ›› Issue (4): 407-411.

• 综述 • 上一篇    下一篇

卵巢癌的分子靶向治疗进展

杨梅琳，李涧，张廷彰，徐丛剑   

  1. 350200 福建省厦门长庚医院妇产科（杨梅琳，李涧，张廷彰）；台湾省桃园市长庚纪念医院妇产科，台湾省桃园市长庚纪念医院妇科肿瘤研究所（张廷彰）；复旦大学附属妇产科医院，复旦大学上海医学院妇产科学系，上海市女性生殖内分泌相关疾病重点实验室，复旦大学生物医学研究院（徐丛剑）
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2016-08-15 发布日期:2016-08-15
  • 通讯作者: 李涧

Progress of Molecular Targeted Therapy in Ovarian Cancer

YANG Mei-lin，LI Jian，ZHANG Ting-zhang，XU Cong-jian   

  1. Department of Obstetrics and Gynecology，Xiamen Chang Gung Hospital，Xiamen 350200，China（YANG Mei-lin，LI Jian，ZHANG Ting-zhang）；Department of Obstetrics and Gynecology，Gynecologic Cancer Research Center，Taoyuan Branch Hospital of Chang Gung Memorial Hospital，Taoyuan，Taiwan Province，China（ZHANG Ting-zhang）；Obstetrics and Gynecology Hospital，Department of Obstetrics and Gynecology of Shanghai Medical School，Fudan University，Shanghai 200011，China（XU Cong-jian）；Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases，Shanghai 200433，China（XU Cong-jian）；Institutes of Biomedical Sciences，Fudan University，Shanghai 200032，China（XU Cong-jian）
  • Received:1900-01-01 Revised:1900-01-01 Published:2016-08-15 Online:2016-08-15
  • Contact: LI Jian

PDF (PC)

5787

摘要： 卵巢癌是妇科肿瘤死亡的首要原因。化疗药物在卵巢癌初始治疗时多数有效，但长时间使用则会引起肿瘤耐药性和正常组织严重损伤等，因此在复发性卵巢癌的治疗中具有局限性。分子靶向治疗作为卵巢癌治疗的新方式，近年获得了多项突破性研究成果，尤其在复发性及耐药性卵巢癌中其可以延长疾病无进展生存期，从而弥补了化疗的不足。其中，抗血管生成类药物和聚腺苷二磷酸核糖聚合酶抑制剂已逐步运用于临床治疗。此外，分子靶向治疗也可通过生物标志物进行分子分型，实现卵巢癌的个体化治疗，这将成为未来治疗研究的新趋势。本文回顾卵巢癌靶向治疗药物的研究进展，分析分子分型运用于卵巢癌治疗的前景，进而探讨分子靶向药物在卵巢癌治疗中的价值。

Abstract: Ovarian cancer is still the leading cause of death from gynecological caner. Chemotherapy usually shows effectiveness in initial treatment of ovarian cancer, but resistance and toxicities increase over time which limits its use in recurrent cases. Targeted therapy offers a new treatment of ovarian cancer and some impressive breakthroughs have been achieved. Especially in the recurrent and resistant ovarian cancer, targeted therapy can prolong the progression free survival that make up for the deficiency of chemotherapy. Among them, antiangiogenic therapy and PARP inhibitors have been gradually applied in clinical treatment. Besides, personalized medicine could probably be realized in the future through biomarker profiles in targeted therapy. We here summarize drugs in targeted therapy of ovarian cancer, describe the prospects of biomarkers and define the role of molecular targeted therapy in the treatment of ovarian cancer.